Leerink reiterates Outperform on MannKind stock, sees overreaction

Leerink Partners reaffirmed an Outperform rating on MannKind and kept its $7.00 price target, arguing the stock looks significantly undervalued even under aggressive bear-case assumptions for Tyvaso DPI royalty erosion. MannKind shares are down about 54% since the TreSMI news and trade at $2.57, roughly 60% below the 52-week high of $6.51, while the firm also sees potential upside from Furoscix’s autoinjector PDUFA date on July 26, 2026. The article also notes mixed peer views, including RBC’s downgrade and H.C. Wainwright’s lower target, but the overall analyst tone remains constructive.

Analysis

The setup is less about the headline and more about where expectations have already been reset. MNKD’s selloff appears to have priced in a near-worst-case royalty decay path plus a weak FUROSCIX ramp, which creates asymmetric upside if either variable stabilizes rather than improves. In biotech, when a single partnership royalty is marked down like this, the stock often needs only modest evidence of durability to re-rate because the market has already moved from discounting risk to discounting the asset’s relevance.

The more interesting second-order effect is competitive signaling: if UTHR can sustain Tyvaso demand despite a soft-mist entrant, that supports the durability of the broader inhaled pulmonary franchise and reduces the odds of a rapid royalty cliff for MNKD. Conversely, if launch friction is real, MNKD’s downside is not linear because the market may eventually realize the cannibalization path is slower than feared and the stock is currently trading as if immediate share loss is inevitable. That makes the next 1-2 quarters more about channel checks and prescription inflection than headline trial news.

Furoscix is the cleaner catalyst because it is self-help, not partner-dependent. The autoinjector PDUFA creates a binary event that could convert a low-growth story into a margin-expansion story, and the implied ~70% COGS reduction means incremental revenue should flow through disproportionately to EBITDA if uptake is real. The key risk is execution delay: any regulatory slip or soft initial uptake would keep the multiple anchored, while a clean approval could force a rapid move as the market recalibrates gross margin leverage over the next 6-12 months.

My contrarian take is that the market is overfitting the TreSMI headline and underweighting the optionality embedded in a de-risked balance sheet after the convertible settlement. The bigger mistake is assuming MNKD is a single-asset royalty proxy; it is increasingly a sum-of-the-parts name with multiple shots on goal, and that profile tends to work best when sentiment is depressed and technicals are washed out.

Key Decisions for Investors

• Initiate a tactical long MNKD position on weakness, sized for a 2-3 month horizon, targeting a re-rating toward the analyst target range if royalty fears stabilize; use a tight stop if channel data confirms accelerated Tyvaso erosion.
• Buy MNKD call spreads into the FUROSCIX autoinjector catalyst window (6-12 months) to express upside convexity while capping premium risk; best risk/reward if implied volatility remains depressed after the selloff.
• Consider a pair trade: long MNKD / short UTHR for investors who believe the market is overpricing Tyvaso durability and underpricing MNKD optionality; exit if UTHR data indicates no meaningful cannibalization.
• For more event-driven accounts, buy MNKD shares only after confirmation of post-catalyst volume expansion or positive prescribing commentary; avoid front-running if liquidity is poor, since the stock can gap on thin trading.
• Use $2.25 as a tactical downside pivot and the prior resistance zone near $3.25-$3.50 as the first take-profit band; above that, a squeeze is plausible if analysts begin revising post-TreSMI assumptions upward.